Canadian Women’s Network Pathway to Silicon Valley Week
perrin2023-04-18T20:06:51+00:00Date: April 17-20
Venue: Silicon Valley
38th Annual EAU Congress
perrin2023-03-04T01:38:20+00:00Date: March 10-13
Venue: In-person, Allianz MiCo, Milano Convention Centre, Milan, Italy
EAU23 is only 1 week away! This is a must-go-to international event dedicated to urology – are you going? Over 4500 abstracts were submitted for EAU23, the third-highest number ever recorded for an Annual EAU Congress.
Hot topics this year include:
Prostate cancer screening and early detection (including imaging), transplant surgery, infections, stones, and major cancers.
Personalized medicine in diagnostics and treatment.
Prostate cancer genomics for practitioners
Men’s health and BPH treatment.
‘Best of EAU’ sessions will be summarised at the end of the congress
Prostate cancer screening and early detection (including imaging), transplant surgery, infections, stones, and major cancers.
Personalized medicine in diagnostics and treatment.
Prostate cancer genomics for practitioners
Men’s health and BPH treatment.
‘Best of EAU’ sessions will be summarised at the end of the congress
SESSION 04
ABSTRACT 0061
4th Annual AIMSSxGairdner AIHC
perrin2023-03-04T00:12:19+00:004th Annual AIMSSxGairdner AI Healthcare Conference
Date: March 10-12
Venue: In-person, and virtual, The Matrix Hotel, Edmonton, Alberta
PUA 2023
perrin2023-03-04T00:02:03+00:0068th Prairie Urological Association Annual Meeting – PUA 2023
Date: March 03-05
Venue: In-person, Lake Louise, Alberta
COO Catalina Vasquez and CCO Colin Coros are in beautiful Lake Louise for the PUA conference
Catalina Vasquez is presenting ClarityDX Prostate: an accurate way to detect clinically significant prostate cancer.
We are proud to be a scientific program session sponsor for this event.
Please reach out to us by DM to chat about our ClarityDX Prostate test.
#ClarityDX_Prostate #urology #prostatecancer #diagnostics #precisionmedicine
Please reach out to us by DM to chat about our ClarityDX Prostate test.
#ClarityDX_Prostate #urology #prostatecancer #diagnostics #precisionmedicine
Molecular Oncology: Building predictive disease models using extracellular vesicle microscale flow cytometry and machine learning
perrin2023-01-09T20:17:59+00:00We developed the extracellular vesicle machine learning analysis platform (EVMAP) to improve the prediction of diseases such as cancer. The platform combines extracellular vesicle analysis using microscale cytometry with a machine learning approach to generate predictive models. In this work, we utilized EVMAP to generate a blood test to predict high-grade prostate cancer in men that was significantly more accurate than the prostate-specific antigen test. This platform could be applied to many different diseases.
Catalina Vasquez and Colin Coros at JPM Week 2023
perrin2023-01-06T00:53:33+00:00JPM Week 2023
Date: January 9 to 12
Venue: In-person, San Francisco, CA
Press Release: Nanostics Announces New Member of Board of Directors
perrin2022-11-17T14:38:46+00:00Edmonton, Alberta – Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company.
“We’re excited to announce Aubrey Rankin’s appointment to Nanostics’ Board of Directors. Aubrey’s vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate®,” said John Lewis, CEO of Nanostics.
Nanostics sends thanks to outgoing board member Reg Joseph, CEO of Health City, for his service. Reg’s insights into the Healthcare Industry were instrumental in helping Nanostics advance its lead diagnostic product, ClarityDX Prostate® through clinical studies and position it for regulatory approval.
Desmond Pink at ISEVxTech
perrin2022-11-17T06:10:34+00:00ISEVxTech Conference
Date: November 16 to 18
Venue: In-person, Waikiki Beach Marriot Resort, Honolulu, HI
1. Qualifying EV Technologies for Regulated and non-Regulated Research
2. Multi-angle flow cytometry illustrates the refractive index complexity
of commonly evaluated biological samples for extracellular vesicle analysis
perrin2022-11-22T17:07:22+00:00
CanPath Webinar with Dr. John Lewis
WEBINAR TO BE RESCHEDULED
Webinar: Predicting diseases through machine learning models
Date: Tuesday, November 22. 2022. New date TBD – please check back for updates.
Venue: Online – for more details and to register go to Event Link
Can Machine Learning models predict disease? Dr. John Lewis, Bird Dogs Chair in Translational Oncology at the University of Alberta, and CEO of Nanostics will talk about creating disease prediction models using CanPath questionnaire data, to help us understand the global risk factors of diseases like prostate cancer and how these risk factors differ for different populations.
News Release: Recognizing 10 years of philanthropic support for prostate cancer research
perrin2022-10-13T05:02:22+00:00Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation.
Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs Chair in Translational Oncology, a position to be held by researcher Dr. John Lewis. For the last 10 years, Dr. Lewis has held the Frank and Carla Sojonky Chair in Prostate Cancer Research, made possible by a $5 million endowment from the Bird Dogs. Taking over from Dr. Lewis in this position will be surgeon-scientist, Dr. Adam Kinnaird.
